Oculis Holding AG (OCS) shares ended the last trading session 8.2% higher at $14.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The company is developing OCS-01, a topical eye drop candidate for treating diabetic macular edema and inflammation and pain following cataract surgery, OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease and ...

Group 1 - Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care, with a differentiated pipeline of innovative product candidates [2] - The company will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference, H.C. Wainwright 26th Annual Global Investment Conference, and Baird Global Healthcare Conference [1] - Oculis' product pipeline includes OCS-01 for diabetic macular edema and post-cataract surgery inflammation, OCS-02 for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis [2] Group 2 - The management team of Oculis is experienced and has a successful track record, supported by leading international healthcare investors [2] - The company is headquartered in Switzerland and has operations in the U.S. and Iceland, aiming to improve the health and quality of life of patients worldwide [2] - Interested investors can request one-on-one meetings during the conferences through their respective representatives at the sponsoring institutions [1]

Exhibit 99.1 Oculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents | Unaudited Condensed Consolidated Interim: | | | --- | --- | | Statements of Financial Position as of June 30, 2024 and December 31, 2023 | 3 | | Statements of Loss for the three and six months ended June 30, 2024 and 2023 | 4 | | Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 | 5 | | Statements of Changes in Equity for the six months ended June 30, 2024 ...

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company's press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with the SEC on form 6-K, are attached. Attachments ...

Core Insights - Oculis Holding AG reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab), indicating potential for the first precision medicine in Dry Eye Disease (DED) [1][3] - The Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024 [1][4] - A pre-NDA meeting with the FDA was completed in August for OCS-01, with NDA submission anticipated in Q1 2025 [1][6] Clinical Highlights - OCS-01 for DME: Patient enrollment in Phase 3 DIAMOND trials exceeded expectations, reaching 35% for DIAMOND-1 and 23% for DIAMOND-2 by the end of June 2024 [4] - OCS-02 (licaminlimab) in DED: Positive results from the Phase 2b RELIEF trial showed improvements in multiple regulatory efficacy endpoints, particularly in patients with the TNFR1 genetic biomarker [4][3] - OCS-05 in AON: Enrollment in the Phase 2 ACUITY trial is complete, with topline readout expected in Q4 2024 [4][6] Financial Highlights - As of June 30, 2024, the company had cash, cash equivalents, and short-term investments totaling $131.2 million, an increase from $109.0 million as of December 31, 2023 [7] - Research and development expenses for Q2 2024 were $18.2 million, up from $6.9 million in Q2 2023, primarily due to increased clinical trial expenses [7][8] - The net loss for Q2 2024 was $23.0 million, compared to $14.3 million in Q2 2023, driven by higher clinical development costs [7][8] Corporate Developments - The company raised $59 million in an oversubscribed registered direct offering and listed on the Nasdaq Iceland Main Market [5] - New appointments to the Board of Directors and Scientific Advisory Board aim to strengthen the company's development and commercial expertise [5] - The company plans to consult with the FDA in Q1 2025 regarding the OCS-02 (licaminlimab) program in DED [6]

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED) Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024 Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following ocular surg ...

Company Overview - Oculis is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company has a differentiated pipeline with multiple innovative product candidates, including OCS-01 for diabetic macular edema and post-cataract surgery inflammation, licaminlimab (OCS-02) for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis [3] - Oculis is headquartered in Switzerland and operates in the U.S. and Iceland, aiming to enhance the health and quality of life for patients globally [3] Management and Events - Riad Sherif, M.D., the CEO of Oculis, will participate in a panel discussion on "Derisked Late-stage Candidates for Retinal Disorders" on August 15, 2024 [2] - A virtual company presentation will also be available on-demand on the same date [2] - Oculis management will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference [4]

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award. "Prof. Ramin Tadayoni was an exceptional friend and a highly accomplished and world-renowned retina specialist that, as an advisor, played a key part in Oculis progress since its inception, and most recently as its Chief Scient ...

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award. "Prof. Ramin Tadayoni was an exceptional friend and a highly accomplished and world-renowned retina specialist that, as an advisor, played a key part in Oculis progress since its inception, and most recently as its Chief Scienti ...

ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results from its Phase 2b RELIEF trial with licaminlimab, a novel anti-TNFα biologic eye drop with an established dual anti-inflammatory and anti-apoptotic mechanism of action in patients with dry eye disease (DED). For the full trial population (n=122): Treatment effect favoring licaminlima ...